Company intelligence / Profile preview
Character Biosciences
Jersey City, New Jersey, United Statescharacterbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Character Biosciences has raised $93 million in Series B funding to advance its lead candidates CTX114 and CTX203 into clinical trials. The company has partnered with over 150 ophthalmology centers and collected data from over 6,500 patients to reclassify AMD into genetically-defined subtypes.
- Therapeutic areas
- Ophthalmology
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Bausch + Lomb (announced January 2025)
Beyond the preview
Go deeper on Character Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Character Biosciences.